Insilico teams up with US firm to build AI models predicting disease decades ahead

Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage advancements in AI and the growing $5.3 trillion global longevity market driven by aging populations.